Search Results

FDA Approves New Drug for the Most Common Form of Leukemia in Adults

We Dare to Dream so Their Dreams Come True

Did you know that blood cancer is the most common cancer diagnosis for children, accounting for 40% of pediatric cancer cases? In fact, nearly 55,000 children and adolescents in the United States currently have blood cancer or are in remission from blood cancer.

Ponatinib

Ponatinib is FDA approved for the treatment of adult patients with:

Nilotinib

Tasigna® is FDA approved for the treatment of

Highlights from ASH 2021

The American Society of Hematology (ASH) annual meeting is the premier scientific forum on blood cancers. More than 5,000 potentially game-changing research abstracts were presented at this year’s meeting. Every year, I come away with a strengthened sense of hope about new treatments on the horizon and renewed pride in The Leukemia & Lymphoma Society’s (LLS) role in supporting so many of them.

The Leukemia & Lymphoma Society Receives $17 Million from the Mike and Sofia Segal Family Foundation to Accelerate Progress in the Treatment of Chronic Myelomonocytic Leukemia

Charlotte in 2022 standing with arms crossed

Young Advocate, Big Goals: Charlotte’s Story

Imagine going to the doctor for a cold only to learn you actually have leukemia. That’s how Charlotte's experience with blood cancer began in 2018.

“The doctor diagnosed it as strep throat,” Charlotte remembers. When the antibiotics didn’t work, she “went to another doctor who diagnosed it as something else.”

Ushering In a New Era of Pediatric Blood Cancer Treatment and Care

We caught up with Gwen Nichols, MD, Chief Medical Officer at The Leukemia & Lymphoma Society (LLS), to share the progress we’re making to bring cures and better care to children with blood cancer through The LLS Children’s Initiative.

Tell us about The LLS Children’s Initiative and why it’s so important to you and LLS.

Pluripotent Stem Cell-derived CAR-T and CAR-NK Cells for Immunotherapy of Leukemia and Lymphoma

Cytotoxic cells of the immune system, including T and NK cells, can be targeted to seek out and destroy leukemia, lymphoma and myeloma cells by engineering them to express chimeric antigen receptors (CARs) which empower the cell to home to and kill the cancer cells. Typically, such CAR-T and CAR-NK cells are generated from a patient's own blood, but sometimes heavy pre-treatment with chemotherapy leaves inadequate supplies of T and NK cells.

New Drug Approval Moves Us Closer To Long-Term Control of Multiple Myeloma

First Day Message from LLS's New President and CEO

A researcher analyzes a specimen in a test tube.

Blood Cancer Research Poised for Another ‘Banner Year’ in 2024

More than 25,000 medical professionals from across the world came together in December to discuss the latest blood cancer developments during the annual meeting of the American Society of Hematology (ASH). This annual event gives us the opportunity to think about what advances are on the horizon as LLS works to strengthen cures, care and quality of life for people with blood cancer and their families.

Mother of Skateboarding Legend Dylan Rieder Running San Diego Marathon in His Honor

Andy Gordon during a training ride in Phoenix

How You Can Help Patients Far Into the Future

6-Thioguanine

6-Thioguanine is FDA approved for remission induction and remission consolidation treatment of acute nonlymphocytic leukemias.

The Leukemia & Lymphoma Society Denounces Federal Actions that Threaten Cancer Patients

Rgenta Therapeutics Joins The Leukemia & Lymphoma Society Therapy Acceleration Program

The Leukemia & Lymphoma Society Kicks Off Light The Night Fall Campaign

LLS National Research Registry Progress Report - Chronic Lymphocytic Leukemia

Leukemia Patient’s Legacy Helps Drive Innovative Cancer Clinical Trial

UCLA Health Joins The Leukemia & Lymphoma Society’s Innovative Clinical Trial

Suggested Reading - My Blood Brother: A Story About Childhood Leukemia

By Elizabeth Murphy-Melas and Mary Kate Wright (Illustrator)
Health Press NA Inc., 2010, 32 pages
ISBN 9780929173566
Ages 4-10

This touching book explores the dynamics of a family dealing with childhood leukemia. Sam and his older brother, Stefan, learn together that Sam has leukemia. The story shows the emotional turmoil a family endures while coping with a diagnosis of childhood cancer. Although Sam is only seven years old, he learns about how the disease affects his body and the terminology related to his illness. My Blood Brother provides support for the patient, siblings, parents, friends and extended family. The illustrations are done by an award-winning medical illustrator who uses color and technique to provide comfortable, soothing illustrations in contrast with the emotionally charged story line. Parents and young children may benefit from this book.

Targeting non-genetic mechanisms of therapeutic resistance in Acute Myeloid Leukaemia

Drug resistance in AML can develop via a non-genetic process which remains poorly understood. Using our novel cellular barcoding technology that can trace the growth of thousands of cancer cells, our research will identify genes that are switched on or off in AML cells that lead to drug resistance and relapse. This work will reveal the factors underpinning non-genetic drug resistance that may be targeted with new drugs to prevent relapse and ultimately improve quality of life and survival.